Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non-Small Cell Lung Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35333492/
Purpose: This study assessed the effects of tislelizumab, a programmed cell death protein 1 inhibitor, in combination with chemotherapy versus chemotherapy alone as first-line treatment on health-related quality of life...
Discussion: The addition of tislelizumab to platinum-based chemotherapy was associated with improvements in nSQ-NSCLC patients' HRQoL as well as the important disease-specific symptoms of coughing, chest pain, and dyspnea.
The association between skeletal muscle measures and chemotherapy‐induced toxicity in non‐small cell lung cancer patients
Source : https://onlinelibrary.wiley.com/doi/10.1002/jcsm.12967
Corine de Jong , Najiba Chargi , Anne S.R. van Lindert , Pim A. de Jong , Alwin D.R. Huitema , Toine C.G. Egberts , Remco de Bree , Vera...
Conclusions: Non-small cell lung cancer patients with pretreatment low SMM are at significant higher risk for haematological toxicities grade 3/4 and DLT. NSCLC patients with high SMD are at significant lower risk for DLT. Further studies should be aimed to investigate whether platinum dosing based on skeletal muscle measurements and/or...
-
Albert Dekker4yrit makes sense to me
Hsa_circRNA_0017620 regulated cell progression of non-small-cell lung cancer via miR-520a-5p/KRT5 axis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35302673/
doi: 10.1002/jcla.24347. Online ahead of print. 1 Department of Oncology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China. 2 Department of Cardiothoracic Surgery, The Central Hospital...
Conclusion: In this study, we found that hsa_circ_0017620 played an important role in NSCLC progression. Hsa_circ_0017620 regulated cell proliferation, invasion, and migration through targeting miR-520a-5p/KRT5 axis in NSCLC, providing a potential new target for the treatment and diagnosis of NSCLC.
Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis
Source : https://www.futuremedicine.com/doi/10.2217/fon-2021-0885
Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related mortality across the world. Non-small-cell lung cancer (NSCLC) accounts for 85–90% of all lung...
Conclusion: Overall, the network meta-analysis included 36 RCTs on 24 interventions in patients with previously untreated EGFRm advanced NSCLC and compared key efficacy and safety end points. The analysis showed ramucirumab erlotinib to be comparable to best-in-class treatment options. More mature data from the included studies, should it...
TMEM139 prevents NSCLC metastasis by inhibiting lysosomal degradation of E-cadherin - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35302694/
Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and has the highest mortality rate among all solid tumors. It is characterized by early metastasis, and...
Conclusion/Relevance: Mechanistically, we found that TMEM139 directly interacts with E-cadherin at the plasma membrane and at focal adhesion sites. Moreover, TMEM139 can prevent the lysosomal degradation of E-cadherin, which inhibits EMT, migration and invasion of NSCLC cells both in vitro and in vivo. Our study not only expands our...